Clinical News

NICE guidance on the use of vedolizumab in Crohn's disease

Wednesday, 26 August 2015 08:53

Single Technology Appraisal (STA) - Vedolizumab for the treatment of adult patients with moderately to severely active Crohn's disease [ID690]

The Final Guidance will be published on the NICE website: on 26th August 2015. There will also be a version of the guidance available for people using services, carers and the public called 'Information for the public'. Additionally, the documentation used to develop the guidance such as the underpinning evidence submissions, will remain on the website.

A copy of the guidance is available for you to download from NICE Docs:

"The BSG welcomes the publication of this guidance on the use of Vedolizumab in Crohn's disease. A significant number of patients suffering from Crohn's disease fail to benefit from anti-TNF therapy, and for them the availability of a drug therapy that has a completely different mode of action, with good trial evidence of efficacy and safety is most welcome."

Dr AB Hawthorne,
IBD section chairman

Applications for Future Hospital 2015 development sites open in September

Friday, 21 August 2015 13:24

The Future Hospital Programme (FHP) is looking for projects currently delivering integrated care for people across a health economy and aligned to the principles set out in the Future Hospital Commission report. The FHP is keen to work with project teams who are developing more efficient and cost-effective healthcare models for people with long-term conditions or complex health needs.

Applications open on 7 September 2015, and the submission deadline is 2 October 2015.

Click here for selection criteria details or This e-mail address is being protected from spambots. You need JavaScript enabled to view it . Click here for more information about current FHP development sites.

Through the 'Tell us your story' initiative, the FHP is showcasing examples of good practice to improve patient care, which will feature as case studies on the RCP website. To share your story with us download a form here.

ACE Programme call for applications to pilot new diagnostic pathways

Friday, 21 August 2015 08:50

The ACE Programme, sponsored by NHS England's National Clinical Director for Cancer, Sean Duffy, has invited applications to pilot a new diagnostic pathway for patients with 'non-specific but concerning symptoms'. This pathway incorporates a Multidisciplinary Diagnostic Centre (MDC), a concept from Denmark where patients undergo several diagnostic tests in one location, leading to faster diagnosis.

This follows on from the Independent Cancer Taskforce's strategy (July 2015), which recommended MDCs as an effective way to address the weakness in the system with regard to patients who go back and forth between primary and secondary care due to a lack of an effective referral pathway.

The ACE Programme would like to work with 5 NHS pilot sites to test MDCs, and evaluate how far an MDC based pathway can lead to:

  • A shift from late to early diagnosis of cancer at stages I or II, when they are potentially curable
  • A reduction in diagnoses numbers from emergency presentations or sub-optimal routes
  • An overall improvement in patient experience

The deadline for applications is September 11th 2015.

Further information can be found here.

New Global Enteral Device Connector

Wednesday, 12 August 2015 09:13

Dr Sheldon Cooper (Chair, BAPEN Medical) & Prof Alastair Forbes (Chair, BSG Small Bowel & Nutrition Committee)

A new International Standard (ISO 80369-3) is being published this year and covers all connectors on enteral devices.

In order to comply with the International Standard, a new global enteral feeding device connector design (named ENFit) will be introduced across the UK from September 2015. The ENFit introduction will be a 2-stage process, with transition giving sets and gravity sets made available from September 2015, followed by ENFit feeding tubes and syringes being introduced from March 2016.

To facilitate the smooth transition to the ISO standard, a group made up of industry, clinical and NHS stakeholders was formed and named the EPSG (Enteral Plastic Safety Group). The EPSG represents all leading UK enteral feeding devices suppliers, with clinical representation from the PENG of the BDA, NNNG and supported by PINNT, BAPEN and BPNG. The following companies are members of the EPSG: Abbott; Corpak; Covidien; Fresenius Kabi; GBUK Enteral (Enteral UK); Intervene; Medicina; Nutricia; Vygon. EPSG member companies and NHS Supply Chain have agreed not to place any ENFit enteral feeding device (other than transition giving sets and gravity sets) into the UK market until 14th March 2016. It is envisaged that this process will minimise disruption to the NHS, whilst maintaining patient safety at all times. For further information about ENFit and how the changeover affects you and your patients, please contact your current enteral devices supplier or any of the following represented clinical groups: PENG of the BDA, NNNG, PINNT, BAPEN, BPNG.

Page 2 of 7